In the last trading session, 2.99 million Hepion Pharmaceuticals Inc (NASDAQ:HEPA) shares changed hands as the company’s beta touched 1.59. With the company’s per share price at $0.16 changed hands at -$0.01 or -4.45% during last session, the market valuation stood at $1.73M. HEPA’s last price was a discount, traded about -1981.25% off its 52-week high of $3.33. The share price had its 52-week low at $0.12, which suggests the last value was 25.0% up since then.

Analysts gave the Hepion Pharmaceuticals Inc (HEPA) stock a consensus recommendation rating of Buy, calculated at a mean rating of 3.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended HEPA as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. Hepion Pharmaceuticals Inc’s EPS for the current quarter is expected to be 0.

Hepion Pharmaceuticals Inc (NASDAQ:HEPA) trade information

Instantly HEPA was in red as seen at the end of in last trading. With action -10.92%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -65.31%, with the 5-day performance at -10.92% in the red. However, in the 30-day time frame, Hepion Pharmaceuticals Inc (NASDAQ:HEPA) is -18.45% down.

The consensus price target for the stock as assigned by Wall Street analysts is 70, meaning bulls need an upside of 99.77% from its current market value. According to analyst projections, HEPA’s forecast low is 70 with 70 as the target high. To hit the forecast high, the stock’s price needs a -43650.0% plunge from its current level, while the stock would need to soar -43650.0% for it to hit the projected low.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 63.67%.

HEPA Dividends

Hepion Pharmaceuticals Inc is expected to release its next quarterly earnings report in March.